RNA Formulation Articles

  1. From Baby KJ To Global Access: The 3 Pillars Of Next-Gen mRNA Expansion 8/8/2026

    Obviously, the transition from RNA vaccines to therapeutics is an “expansion” all on its own; but to do this successfully, we need to expand our science, our products’ deliverability, and our patient access. In the following article, I highlight a few of the best practices and/or innovations that came up in conversation during this event that will play a significant role in helping us expand mRNA’s reach, both scientifically and therapeutically.

  2. The Preclinical Gauntlet: Securing Capital And Designing Regulatory Pathways For Ultra-Rare ASO Drugs (Pt. 2) 8/7/2026

    SynaptixBio CEO Dan Williams explains why funding, regulatory strategy, toxicology, and disciplined execution — not just science — determine success in advancing ultra-rare ASO therapies.

  3. Reprogramming The Tumor Microenvironment: Why RNA Immunotherapy Is Targeting Liver Metastases (Pt. 1) 8/5/2026

    RNA/DNA immunotherapy may overcome liver metastases by reprogramming innate immunity, restoring interferon signaling, and improving responses to checkpoint inhibitors.

  4. Beyond Protein Targets: Why The Regulatory Genome Could Redefine RNA Medicine (Pt. 1) 8/4/2026

    Explore how the regulatory genome and lncRNAs are shifting RNA medicine beyond protein targets, enabling cell-state reprogramming to treat disease at its source.

  5. Beyond Better Models: Why The Future Of AI-Designed mRNA Depends On More Relevant Biological Data 7/31/2026

    AI can optimize mRNA only if it's trained on biologically relevant data. Better therapeutic datasets — not just better algorithms — will drive the next generation of RNA medicines.

  6. The Delivery Challenge For In Vivo Cell Engineering 7/30/2026

    As RNA therapies expand beyond the liver, delivery—not payload design—has become the defining challenge for precise, scalable in vivo cell engineering.

  7. Building An ASO For TUBB4A-Related Leukodystrophy (Pt. 1) 7/28/2026

    SynaptixBio CEO Dan Williams explains how the company selected an ASO for TUBB4A leukodystrophy by balancing potency, safety, and translational rigor to advance a rare disease therapy.

  8. Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics 7/23/2026

    CircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.

  9. Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery 7/22/2026

    As RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.

  10. Beyond Vaccines: Can RNA Sense Gases? 7/20/2026

    Could RNA sense its environment? A new hypothesis explores how RNA may detect temperature and gases, inspiring smarter, adaptive RNA therapeutics.